patients can get back to living their lives rather than spending hours in a hospital chair
Across England, the NHS has begun offering cancer patients a new form of pembrolizumab — an immunotherapy delivered not through a two-hour intravenous drip, but as a brief injection lasting under two minutes. The change touches nearly 14,000 existing patients and reaches across almost thirty cancer types, reclaiming more than 100,000 hours of clinical time each year. In the long arc of medicine, this is a moment where a shift in delivery — not discovery — quietly transforms the human experience of illness.
- Cancer patients who once surrendered entire mornings to treatment chairs can now receive the same immunotherapy in under two minutes, a compression of burden that is difficult to overstate.
- The NHS, already stretched thin, stands to recover more than 100,000 hours of preparation and treatment time annually — capacity that can be redirected toward patients still waiting for care.
- 14,000 patients currently on intravenous pembrolizumab are being transitioned to the injectable form, with early recipients describing the change as a restoration of ordinary life.
- Paired with nivolumab — a similarly rapid immunotherapy introduced last year — the NHS now offers two fast-delivery treatments covering nearly thirty cancer types, signaling a broader shift in how oncology care is structured.
- Hospitals in Bristol, Weston, and Hertfordshire are among the first to administer the new jab, with NHS England framing the rollout as both a patient benefit and a systemic gain.
The NHS has begun administering pembrolizumab as a quick injection rather than a two-hour intravenous infusion — a change that compresses a half-day hospital commitment into a single minute. The drug works by blocking the PD-1 protein that suppresses immune responses, freeing the body to identify and attack cancer cells across nearly thirty tumor types. The new form can be given every three weeks as a one-minute dose, or every six weeks in two minutes.
For the 14,000 patients already receiving the drug by IV, the shift is profound. The old method demanded specialist preparation, clean rooms, and hours of a patient's time per session. Among the first to receive the injection was Shirley Xerxes, 89, from St Albans, who described the contrast with quiet astonishment — hours once lost to a hospital chair now returned to her garden and her life. The accumulated weight of cancer treatment, she suggested, had been lightened in a way the diagnosis itself could not be.
The operational implications are equally significant. Every hour a patient occupies a treatment chair is an hour of staff attention, clinical space, and scheduling capacity consumed. Freeing that time allows hospitals to see more patients and reduce waiting lists. The NHS estimates the switch will unlock over 100,000 hours annually across England.
Pembrolizumab joins nivolumab — a three-to-five-minute immunotherapy injection made available to up to 15,000 patients last year — as the second rapid-delivery cancer treatment on the NHS. Together, they cover almost thirty cancer types. NHS England's cancer leadership has described the development as a genuine win for both patients and the health system: a rare moment where a change in how medicine is delivered, rather than what medicine does, reshapes the daily reality of living with cancer.
The NHS has begun rolling out a new form of cancer immunotherapy that collapses treatment time from a two-hour hospital visit into a single minute. The injectable version of pembrolizumab, administered as a quick jab rather than through an intravenous drip, works by blocking a protein called PD-1 that normally suppresses immune responses. By removing this biological brake, the drug allows the body's own defenses to recognize and destroy cancer cells across nearly thirty different tumor types.
For the roughly 14,000 patients already receiving pembrolizumab through traditional IV infusion, this shift represents a fundamental change in how they experience treatment. The old method required specialist clean rooms, careful preparation by NHS staff, and roughly two hours of a patient's time per session. The new injectable can be given every three weeks as a one-minute dose, or every six weeks as a two-minute injection. The time savings are staggering: the NHS estimates the switch will free up more than 100,000 hours of preparation and treatment time annually across England.
Shirley Xerxes, an 89-year-old from St Albans, was among the first to receive the new treatment. She described the experience with something close to disbelief. Where she once spent an hour or more in a hospital chair, she now sits for minutes. That reclaimed time matters to her—she spends it gardening, living the life that cancer treatment had been consuming piece by piece. For many patients, the burden of cancer care extends far beyond the disease itself. Regular hospital trips, long waits, the exhaustion of repeated visits—these accumulate. Cutting that load in half or more changes the texture of daily existence.
The clinical logic is sound. Pembrolizumab works by the same mechanism as nivolumab, another immunotherapy injection that takes three to five minutes and became available to up to 15,000 patients last year. Together, these two rapid treatments now cover almost thirty cancer types on the NHS. The shift also creates operational breathing room. When patients spend two hours in treatment, they occupy a chair, a room, a staff member's attention. Free that time and the NHS can see more patients, reduce waiting lists, and direct clinical capacity toward people still waiting for their first appointment.
University Hospitals Bristol and Weston NHS Foundation Trust and the East and North Hertfordshire Teaching NHS Trust are among the first sites to offer the new injectable. James Richardson, the national specialty adviser for cancer drugs at NHS England, framed it as a genuine win-win: patients get their lives back, and the health service gains the capacity to treat more people. Peter Johnson, the NHS national clinical director for cancer, echoed the sentiment, describing the treatment as a lifeline and emphasizing that the speed of delivery means patients can return to living rather than enduring endless hospital hours.
What makes this shift significant is not just the technology itself—immunotherapy has been advancing for years—but the practical reimagining of how it reaches patients. The injectable form is not fundamentally different in its mechanism. It is different in its delivery, and that difference ripples outward. A patient who once blocked out a morning or afternoon for treatment can now fit it into a lunch break. A clinical team that once managed a handful of patients per day can now manage more. The NHS, perpetually stretched, gains room to breathe. And thousands of people living with cancer get back hours they thought were lost.
Citas Notables
I can't believe how little time it took. I was only in the chair for a matter of minutes instead of an hour or more.— Shirley Xerxes, 89-year-old patient from St Albans
This immunotherapy offers a lifeline for thousands of patients and it's fantastic that this new rapid jab can now take just a minute to deliver.— Prof Peter Johnson, NHS national clinical director for cancer
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this takes a minute instead of two hours? Isn't the drug doing the same thing either way?
The drug is the same, yes. But time is not abstract for someone with cancer. Two hours in a hospital chair, every few weeks, adds up. It's not just the appointment—it's the travel, the waiting, the disruption to your day. When you compress that to a minute, you're not just saving time. You're saying the treatment can fit into your life instead of your life fitting around the treatment.
And for the NHS itself, what's the real gain?
Capacity. Right now, one patient takes two hours. If you have one chair and one nurse, you see maybe three or four patients a day. Cut that to a minute and suddenly you can see twenty. That's not theoretical—that's 100,000 hours a year freed up. In a system where waiting lists are the constant crisis, that's real breathing room.
Does the injectable version work as well as the IV version?
The source doesn't suggest any difference in efficacy. It's the same drug, same mechanism. The only difference is how it gets into your body and how long that takes. The clinical teams wouldn't switch if it didn't work.
Who benefits most from this change?
The 14,000 people already on pembrolizumab benefit immediately—they get their time back. But there's a second group: people waiting for treatment. When you free up that capacity, waiting lists shrink. That's where the real human impact spreads.
Is this the future of cancer treatment?
It's one piece of it. The NHS now has two rapid immunotherapies covering nearly thirty cancer types. That's a shift toward treatments that fit into life rather than consuming it. Whether that becomes the standard depends on what other drugs can be reformulated this way.